S D Neidich1, W D Green2, J Rebeles2, E A Karlsson3, S Schultz-Cherry3, T L Noah4, S Chakladar5, M G Hudgens5, S S Weir6, M A Beck2. 1. Human Vaccine Institute, Duke University, Durham, NC, USA. 2. Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3. Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA. 4. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 5. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 6. Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract
BACKGROUND: Influenza infects 5-15% of the global population each year, and obesity has been shown to be an independent risk factor for increased influenza-related complications including hospitalization and death. However, the risk of developing influenza or influenza-like illness (ILI) in a vaccinated obese adult population has not been addressed. OBJECTIVE: This study evaluated whether obesity was associated with increased risk of influenza and ILI among vaccinated adults. SUBJECTS AND METHODS: During the 2013-2014 and 2014-2015 influenza seasons, we recruited 1042 subjects to a prospective observational study of trivalent inactivated influenza vaccine (IIV3) in adults. A total of 1022 subjects completed the study. Assessments of relative risk for laboratory confirmed influenza and ILI were determined based on body mass index. Seroconversion and seroprotection rates were determined using prevaccination and 26-35 days post vaccination serum samples. Recruitment criteria for this study were adults 18 years of age and older receiving the seasonal trivalent inactivated influenza vaccine (IIV3) for the years 2013-2014 and 2014-2015. Exclusion criteria were immunosuppressive diseases, use of immunomodulatory or immunosuppressive drugs, acute febrile illness, history of Guillain-Barre syndrome, use of theophylline preparations or use of warfarin. RESULTS: Among obese, 9.8% had either confirmed influenza or influenza-like-illness compared with 5.1% of healthy weight participants. Compared with vaccinated healthy weight, obese participants had double the risk of developing influenza or ILI (relative risk=2.01, 95% CI 1.12, 3.60, P=0.020). Seroconversion or seroprotection rates were not different between healthy weight and obese adults with influenza or ILI. CONCLUSIONS: Despite robust serological responses, vaccinated obese adults are twice as likely to develop influenza and ILI compared with healthy weight adults. This finding challenges the current standard for correlates of protection, suggesting use of antibody titers to determine vaccine effectiveness in an obese population may provide misleading information.
BACKGROUND:Influenza infects 5-15% of the global population each year, and obesity has been shown to be an independent risk factor for increased influenza-related complications including hospitalization and death. However, the risk of developing influenza or influenza-like illness (ILI) in a vaccinated obese adult population has not been addressed. OBJECTIVE: This study evaluated whether obesity was associated with increased risk of influenza and ILI among vaccinated adults. SUBJECTS AND METHODS: During the 2013-2014 and 2014-2015 influenza seasons, we recruited 1042 subjects to a prospective observational study of trivalent inactivated influenza vaccine (IIV3) in adults. A total of 1022 subjects completed the study. Assessments of relative risk for laboratory confirmed influenza and ILI were determined based on body mass index. Seroconversion and seroprotection rates were determined using prevaccination and 26-35 days post vaccination serum samples. Recruitment criteria for this study were adults 18 years of age and older receiving the seasonal trivalent inactivated influenza vaccine (IIV3) for the years 2013-2014 and 2014-2015. Exclusion criteria were immunosuppressive diseases, use of immunomodulatory or immunosuppressive drugs, acute febrile illness, history of Guillain-Barre syndrome, use of theophylline preparations or use of warfarin. RESULTS: Among obese, 9.8% had either confirmed influenza or influenza-like-illness compared with 5.1% of healthy weight participants. Compared with vaccinated healthy weight, obeseparticipants had double the risk of developing influenza or ILI (relative risk=2.01, 95% CI 1.12, 3.60, P=0.020). Seroconversion or seroprotection rates were not different between healthy weight and obese adults with influenza or ILI. CONCLUSIONS: Despite robust serological responses, vaccinated obese adults are twice as likely to develop influenza and ILI compared with healthy weight adults. This finding challenges the current standard for correlates of protection, suggesting use of antibody titers to determine vaccine effectiveness in an obese population may provide misleading information.
Authors: Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: H S Izurieta; W W Thompson; P Kramarz; D K Shay; R L Davis; F DeStefano; S Black; H Shinefield; K Fukuda Journal: N Engl J Med Date: 2000-01-27 Impact factor: 91.245
Authors: H K Talbot; L A Coleman; K Crimin; Y Zhu; M T Rock; J Meece; D K Shay; E A Belongia; M R Griffin Journal: Vaccine Date: 2012-04-03 Impact factor: 3.641
Authors: Jennifer Rebeles; William D Green; Yazan Alwarawrah; Amanda G Nichols; William Eisner; Keiko Danzaki; Nancie J MacIver; Melinda A Beck Journal: J Infect Dis Date: 2019-04-19 Impact factor: 5.226
Authors: Redin A Spann; William J Lawson; Raymond J Grill; Michael R Garrett; Bernadette E Grayson Journal: Physiol Genomics Date: 2017-08-18 Impact factor: 3.107
Authors: Monica Tang; Robert J Henderson; Janet T Holbrook; Loretta G Que; Anne M Mathews; Robert A Wise; Anne E Dixon; Stephen P Peters; Linda Rogers; Lewis J Smith; W Gerald Teague; Jason E Lang Journal: J Allergy Clin Immunol Pract Date: 2018-10-09
Authors: Sarah M Bartsch; Elizabeth A Mitgang; Gail Geller; Sarah N Cox; Kelly J O'Shea; Angie Boyce; Sheryl S Siegmund; Jeffrey Kahn; Bruce Y Lee Journal: J Infect Dis Date: 2020-09-01 Impact factor: 5.226